ClinicalTrials.gg
CompletedNCT03720548Updated Jun 5, 2019

A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)

A Phase 1 interventional study of LY3372993 and Placebo in Alzheimer Disease, sponsored by Eli Lilly and Company. Completed at 11 sites in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-05.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was May 2019, 7 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 99 studies in Alzheimer Disease by Eli Lilly and Company — 13 open to participants now, 19 under way, 8 of them phase 3. Alzheimer Disease · Eli Lilly and Company.

Enrollment
70th of 95
36 · median 95
Started
2018
with 2 others
Phase 1
34 of 99
6 open now
Registered
71st of 99
by date

Among the 99 studies in Alzheimer Disease by Eli Lilly and Company, this one is the 70th largest by enrollment of the 95 interventional ones that give a count, is one of 3 that started in 2018, is one of 34 in phase 1, and was the 71st registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

13 of the 99 studies in Alzheimer Disease by Eli Lilly and Company are open now, in 11 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Alzheimer Disease by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the safety and tolerability of LY3372993 in healthy participants and participants with AD. The study will also investigate how much LY3372993 gets into the bloodstream and test the effects of LY3372993 in participants with AD.

The study has two parts:

  • Part A - Healthy participants will receive LY3372993 or placebo. Part A will last up to 17 weeks;
  • Part B - Participants with AD will receive LY3372993 or placebo. Part B will last about 317 days.
Read the detailed description

In April, 2019, Eli Lilly and Company made a business decision to terminate Part B. No participants were enrolled.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part A:

  • Overtly healthy males or females as determined by medical history and physical examination
  • Are between 18 to 45 years old, inclusive
  • Male participants agree to use a reliable method of during the study and 3 months following the last dose of the product
  • Female participants not of
  • Have a of 18.0 to 32 kilograms per square meter (kg/m²) inclusive

Part B:

  • Present with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild-to-moderate AD
  • Positive florbetapir scan
  • Men or nonfertile women, at least 55 years of age. Nonfertile is defined as hysterectomy and/or bilateral oophorectomy, or amenorrhea for at least 1 year
  • Have up to 2 study partners who can provide health information related to the study about the participant. Study partner(s) will provide a separate written to participate

Exclusion criteria

Exclusion Criteria:

  • Have significant abnormalities in brain magnetic resonance imaging (MRI); or have for MRI
  • Have significant allergic reactions to LY3372993, or related compounds, or have significant allergies to humanized monoclonal antibodies, diphenhydramine, epinephrine, or methylprednisolone
  • Have neurological or psychological illness, or other illnesses that could affect the study results

Part A:

  • Have family history of early onset Alzheimer's Disease (AD)
  • Have impaired cognitive function

Part B:

  • History of intracranial hemorrhage, cerebrovascular aneurysm or arteriovenous malformation, or carotid artery occlusion, or stroke or epilepsy
  • Previously dosed in any other study investigating active immunization against amyloid beta (Aβ)
  • Previously dosed in any other study investigating passive immunization against Aβ within the last 6 months
  • Have current serious or unstable illnesses
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    LY3372993 (Part A)

    LY3372993 administered intravenously (IV) to healthy participants.

    Drug: LY3372993

  • Placebo comparator
    Placebo (Part A)

    Placebo administered IV to healthy participants.

    Drug: Placebo

  • Experimental
    LY3372993 (Part B)

    LY3372993 administered IV to participants with AD. Part B was terminated before any participants received treatment.

    Drug: LY3372993

  • Placebo comparator
    Placebo (Part B)

    Placebo administered IV to participants with AD. Part B was terminated before any participants received treatment.

    Drug: Placebo

Interventions

  • Administered IV.

  • DrugPlacebo

    Administered IV.

06

What researchers measure

Primary outcomes

  1. Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Baseline up to Day 562

Secondary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve of LY3372993 After a Single Dose

    PK: AUC of LY3372993 After a Single Dose

    Time frame: Predose up to Day 85

  2. PK: Maximum Observed Concentration (Cmax) of LY3372993 After a Single Dose

    PK: Cmax of LY3372993 After a Single Dose

    Time frame: Predose up to Day 85

  3. PK: AUC of LY3372993 at Steady State after Multiple Doses

    PK: AUC of LY3372993 at Steady State after Multiple Doses

    Time frame: Week 14 through Week 18

  4. PK: Cmax of LY3372993 at Steady State After Multiple Doses

    PK: Cmax of LY3372993 at Steady State After Multiple Doses

    Time frame: Week 14 through Week 18

  5. Pharmacodynamics (PD): Change from Baseline in Amyloid Load

    Amyloid load measured by florbetapir F18 positron emission tomography (PET) scan

    Time frame: Baseline, Week 28

07

Study locations

11 sites
  • Collaborative Neuroscience Network - CNS
    Long Beach, California 90806, United States
  • Covance Clinical Research Inc
    Daytona Beach, Florida 32117, United States
  • Avail Clinical Research LLC
    DeLand, Florida 32720, United States
  • MD Clinical
    Hallandale Beach, Florida 33009, United States
  • BioClinica Inc
    Orlando, Florida 32806, United States
  • IMIC, Inc.
    Palmetto Bay, Florida 33157, United States
  • Progressive Medical Research
    Port Orange, Florida 32127, United States
  • BioClinica Inc
    The Villages, Florida 32162, United States
  • Atlanta Center of Medical Research
    Atlanta, Georgia 30331, United States
  • Carolina Phase 1 Research (Wake M3)
    Raleigh, North Carolina 27612, United States
  • PRA Health Sciences
    Salt Lake City, Utah 84124, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in May 2019, 6 months.

Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 6 months is below that.

Counting every sponsor, half of 234 studies reached it within 18 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2018
First posted
Oct 25, 2018
StartActual
Nov 5, 2018
Primary completionActual
May 14, 2019
CompletionActual
May 14, 2019
Last update
Jun 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03720548
Responsible party
Sponsor
First posted
Oct 25, 2018
Start date
Nov 5, 2018
Primary completion
May 14, 2019
Completion
May 14, 2019
Last update
Jun 5, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remternetug

Start the discussion